These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8888741)

  • 1. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
    J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
    Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
    Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
    J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
    J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
    Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
    Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
    van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
    J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
    Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
    Ann Oncol; 1993 Sep; 4(8):673-8. PubMed ID: 8240998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.